Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Tumor Immunotherapy01:27

Tumor Immunotherapy

723
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
723
Cancer Vaccines01:30

Cancer Vaccines

554
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
554
Cancer Therapies02:49

Cancer Therapies

8.1K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

4.2K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
4.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

463
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
463

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Tumour Mutational Burden and Its Relationship with Clinical Outcomes in Locally Advanced and Recurrent/Metastatic Adenoid Cystic Carcinoma with and Without NOTCH Pathway Activation.

Cancers·2026
Same author

Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.

Science advances·2026
Same author

Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Tissue-specific fibroblast lipid cues impose the rate of epithelial cancer invasion.

Nature metabolism·2026
Same author

Retinopathy caused by a primary immune regulatory disorder - the spectrum of AIRE-associated retinopathy: case series and literature review.

Eye (London, England)·2026
Same author

The TCR in CAR T cell therapy: use it or lose it?

Cancer gene therapy·2026

関連する実験動画

Updated: Oct 10, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.7K

免疫療法としての腫瘍性ウイルス療法

Alan Melcher1, Kevin Harrington1, Richard Vile2

  • 1The Institute of Cancer Research, London, UK.

Science (New York, N.Y.)
|December 9, 2021
PubMed
まとめ

腫瘍溶解性ウイルス治療に対する免疫反応を理解することが重要です. この知識は癌の治療のための新しい組み合わせの治療法の開発を可能にします.

科学分野:

  • 免疫学
  • 腫瘍学
  • ウイルス学

背景:

  • 腫瘍溶解性ウイルス療法では 選択的に癌細胞を感染させ破壊します
  • 腫瘍解毒ウイルスの有効性は,宿主の免疫系によって著しく影響を受けます.
  • 免疫反応を特定し特徴づけることは,治療戦略を最適化するために極めて重要です.

研究 の 目的:

  • 腫瘍溶解性ウイルス治療における免疫反応の役割を探求する.
  • 腫瘍解消性ウイルス治療を他の治療法と併用する際の潜在的相乗効果を調査する.
  • 新しい組み合わせの免疫療法の開発のための基礎を築く.

主な方法:

  • 腫瘍の微小環境における免疫細胞の浸透と活性化の分析
  • サイトカインとケモカインのプロフィールの評価
  • 臨床前モデルにおける腫瘍の成長と生存の評価

主要な成果:

  • 特定の免疫細胞集団とシグナル伝達経路は,腫瘍解消性ウイルス治療の有効性の重要な媒介物として特定されました.
  • 免疫反応を調節することで,ウイルス性腫瘍解離が促進されるという証拠があります.
  • 予備的なデータは組み合わせ戦略の可能性を示しています.

さらに関連する動画

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.2K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.6K

関連する実験動画

Last Updated: Oct 10, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.7K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.2K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.6K

結論:

  • 腫瘍解消性ウイルス治療の免疫認識は成功の決定的な要因です.
  • これらの免疫反応をターゲットにしたり 増強したりすることで 治療の成果が向上する見込みです
  • 併用療法に関するさらなる研究が必要である.